Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Sushma Gurumurthy"'
Autor:
Vitor M Faca, Kenneth S Song, Hong Wang, Qing Zhang, Alexei L Krasnoselsky, Lisa F Newcomb, Ruben R Plentz, Sushma Gurumurthy, Mark S Redston, Sharon J Pitteri, Sandra R Pereira-Faca, Renee C Ireton, Hiroyuki Katayama, Veronika Glukhova, Douglas Phanstiel, Dean E Brenner, Michelle A Anderson, David Misek, Nathalie Scholler, Nicole D Urban, Matt J Barnett, Cim Edelstein, Gary E Goodman, Mark D Thornquist, Martin W McIntosh, Ronald A DePinho, Nabeel Bardeesy, Samir M Hanash
Publikováno v:
PLoS Medicine, Vol 5, Iss 6, p e123 (2008)
The complexity and heterogeneity of the human plasma proteome have presented significant challenges in the identification of protein changes associated with tumor development. Refined genetically engineered mouse (GEM) models of human cancer have bee
Externí odkaz:
https://doaj.org/article/d24da75bd6e447fd91e328ee33f09d06
Autor:
Kimberly A Kelly, Nabeel Bardeesy, Rajesh Anbazhagan, Sushma Gurumurthy, Justin Berger, Herlen Alencar, Ronald A Depinho, Umar Mahmood, Ralph Weissleder
Publikováno v:
PLoS Medicine, Vol 5, Iss 4, p e85 (2008)
BackgroundPancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. The development of molecular markers and im
Externí odkaz:
https://doaj.org/article/4d13fe7230674b9cacf744f778eb9e1b
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Supplementary Figures S1-S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447a2faa43430fbac4574cf80676b109
https://doi.org/10.1158/1078-0432.22477526
https://doi.org/10.1158/1078-0432.22477526
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Purpose:While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b977133483ab014e3abfe875a2074603
https://doi.org/10.1158/1078-0432.c.6529685
https://doi.org/10.1158/1078-0432.c.6529685
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e329b32ceccaccb01d825f32846ab6
https://doi.org/10.1158/1078-0432.22477523
https://doi.org/10.1158/1078-0432.22477523
Autor:
David Alvarez, Guillemette Masse-Ranson, Saikiran K. Sedimbi, Phylicia Wisti, Lisa Rodriguez, Jordan Santana, Taylor Manning, Tim Towner, Ben Geilich, Cosmin Mihai, Ankita Mishra, Sushma Gurumurthy, Josh Frederick, Ulrich H. von Andrian, Jonathan Hoggatt, Melissa J. Moore, J. Rodrigo Mora
Gene correction of hematopoietic stem cells (HSC) is a promising therapeutic approach for multiple disorders. Current methods, however, require HSC collection from patients, gene correction duringex vivoculture, and re-infusion of corrected HSC into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::597ff87ba90866eb90d8018250df7bb4
https://doi.org/10.1101/2022.12.15.520650
https://doi.org/10.1101/2022.12.15.520650
Autor:
Kristen Arnold, Chris Morehouse, Eleanor Clancy-Thompson, Katharina Deschler, Susannah Hewitt, Russell Karp, Ameya Apte, Chris Bagnall, Faith Musenge, Darren Potz, David A. Leinster, Kathy Mulgrew, Ankita Mishra, Gordon Moody, Maja Sedic, Joshua Frederick, John Zielinski, Fabien Garcon, Sushma Gurumurthy, Nadia Luheshi, Michal Sulikowski, Steve Novick, Han Si, Philip Martin, Grace Adjei, James Moynihan, Jean-Martin Lapointe, Amanda Watkins, Shannon Burke, Ronald Herbst, Dyane Bailey, Robert W. Wilkinson
Publikováno v:
Clinical Cancer Research. 26:6284-6298
Purpose: While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models;
Autor:
Darren Potz, Susannah Hewitt, Ronald Herbst, John Zielinski, Kristen Arnold, Robert W. Wilkinson, Ameya Apte, Sushma Gurumurthy, Ankita Mishra, Russell Karp, Andrew Leinster, Dyane Bailey, Faith Musenge, Joshua Frederick, Nadia Luheshi, Grace Adjei
Publikováno v:
Cancer Research. 78:1758-1758
As a central mediator of TH1 immune responses, interleukin 12 (IL-12) in the tumor microenvironment (TME) plays a key role in driving anti-tumor immunity. Recombinant IL-12 has been reported to promote CD8+ cytotoxic T cell (CTL) dependent anti-tumor
Autor:
Nabeel Bardeesy, Sushma Gurumurthy
Publikováno v:
Drug Discovery Today: Disease Models. 3:161-166
Activating Kras mutations are among the most common oncogenic alterations in human cancers. Kras signaling is required for the sustained malignant growth of numerous cancer types hence this pathway is a strong candidate for drug development. Because
Publikováno v:
Molecular and Cellular Biology. 25:1146-1161
Despite distinct dissimilarities, diverse cancers express several common protumorigenic traits. We present here evidence that the proapoptotic protein Par-4 utilizes one such common tumorigenic trait to become selectively activated and induce apoptos